Clinical outcomes of adjuvant taxane plus anthracycline versus taxane-based chemotherapy regimens in older adults with node-positive, triple-negative breast cancer: A SEER–Medicare study

Advocate-BREAST80+: A Comprehensive Patient and Advocate-Led Study to Enhance Breast Cancer Care Delivery and Patient-Centered Research in Women aged ≥ 80 years

“…The reasons for therapy decline in older patients may include duration of therapy, perceived unclear benefit of therapy, concerns regarding the potential for therapies to exacerbate preexisting medical conditions and/or cause new problems, financial concerns, and communication barriers (e.g., hearing or visual impairments that make it difficult to understand the benefits of a given cancer treatment) [12,13]. While avoidance of potentially toxic therapies is often appropriate in BC P80+ as risks may outweigh benefits, some older BC patients do benefit from adjuvant chemotherapy [14,15]. The ADVANCE (ADjuVANt Chemotherapy in the Elderly) trial assessed the feasibility of two (neo)adjuvant chemotherapy regimens in parallel-enrolling cohorts of older persons (≥ 70 years) with human epidermal growth factor receptor 2 (HER2)-negative BC [16].…”